Authors

Bridging the Gap: A Large Pharma Blueprint

Five steps for organizations in bringing enterprise-level strategies to life.

Why Advisory Committees Remain Essential in an Era of Complex Medicines

Dismissing the role of independent, outside experts in FDA decision-making weakens the drug review process.

From Advantage to Essential: How Daily Data & AI Alerts Transform Commercial Functions

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Social Listening Is Becoming a Medical Affairs Imperative

Social listening can help medical affairs and medical information teams identify knowledge gaps, strengthen scientific exchange and respond to changing stakeholder needs faster and at greater scale.

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Elevating and De-Risking Your Drug Portfolio Strategy With AI

Artificial intelligence (AI) can improve risk assessment and decision-making in drug development by applying objective, data-driven criteria consistently. Companies should focus on the quality of data, selecting the right AI use cases, and leveraging external partners to maximize the potential of AI.

The CFO as the enterprise decision engine: Why pharma finance functions are being rebuilt and what the next 24 months demand

Pharma CFOs are navigating an increasingly complex business environment. From portfolio investments and pricing pressure to manufacturing strategy and AI adoption, the pace and stakes of decision-making continue to rise. The organizations pulling ahead are the ones that rely on finance as an enterprise decision engine—using data, insight, and judgment to help the business allocate capital more effectively, respond faster to change, and create long-term value.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

From ‘Pilotitis’ to Productivity: Reimagining AI’s Role in R&D

A blueprint for how companies can move from isolated pilots toward effective AI implementation.

The Evolution of Patient Assistance Programs: A Holistic, Person-Centered Approach

Unlocking the Next Frontier in AI-Driven Drug Discovery

The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

How Life Sciences Companies Can Create Real Impact With Patient Engagement

A “maturity curve” can help organizations move engagement beyond performative gestures to a strategic asset.

Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies

Mike Faddoul, Partner, Audit & Assurance, Crowe, makes the case that gross-to-net accounting deserves the same pre-launch rigor as commercial strategy.

Driving Field Excellence with AI-Enhanced Rep Support

The Next Physician Burnout Crisis Is Scientific Overload

A recent national survey published in The Permanente Journal gives us the clearest look in more than a decade at why physicians are leaving clinical practice early. The findings, drawn from nearly 1,000 clinically inactive doctors who completed residency between 2000 and 2022, show a striking shift in when physicians are leaving practice. The mean age at departure is now 48.1, compared with 57.1 in a comparable cohort studied in 2008. In other words, physicians are leaving roughly nine years earlier than a generation ago.

From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived

Greater Miami is rapidly emerging as an international biotech hot spot—as capital, talent, and infrastructure converge to transform the region from a tourism-driven economy into a globally connected life sciences innovation hub.

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.

Scaling AI's Promise in Healthcare: The Time is Now

In Part 2 of our podcast video episode with ZS CEO Pratap Khedkar, he breaks down pharma's need to move beyond AI pilots to scalable impact—and how companies can "go from informing to solving" while navigating trust, regulation, and a rapidly shifting patient dynamic.

The Three Pillars of Pharma’s New Commercial Model

Identifying the priorities that translate to strong business outcomes—and separating the top performers from the average brands.

From Evidence to Access: How Real-World Data Delivers for Patients

Regulatory approval is no longer simply representative of the finish line—but instead can serve as a key launching point to evidence-driven insights that create more timely and broader product access.

Nitrosamine Detection in Pharmaceuticals: A Faster, Greener, and More Effective Approach

How to Overcome Market Access Hurdles for Inpatient Drug Launches

Fast Is Not the Same as Trustworthy: The Data Standing Behind an Effective AI Answer

Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.

FDA’s New Accelerated Approval Draft Guidance

What biopharma companies need to know about this evolving regulatory pathway.

De-Risking Clinical Development: Strategic Multipliers in Global Trials

Effective governance models in CRO-sponsor partnerships: Lessons from the Bayer-Parexel collaboration

New Federal Market Access Restrictions: Optimizing Manufacturer Strategies as PBMs Gain Power

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.